European Journal of Molecular & Clinical Medicine

ISSN 2515-8260 Volume 09, Issue 03, 2022

ORIGINAL RESEARCH

Immunological profile of youth onset Diabetes Mellitus patients

[1]Sanjay Nath Jha, [2]Gopi Nath Dubey, [3]Sushil Kumar, [4]Vinya Nand Jha

[1,2,3]Assistant Professor, [4]Associate Professor, Dept. of Medicine, Darbhanga Medical College, Laheriasarai, Bihar, India

Correspondence:
Sanjay Nath Jha
Assistant Professor, Dept. of Medicine, Darbhanga Medical College, Laheriasarai, Bihar, India

ABSTRACT

Background & objectives: There has been a rise in the occurrence of diabetes mellitus in the youth population of India. There is restricted information accessible on the immunological profile of youth beginning diabetes mellitus (DM) particularly in type 2. Hence, this study was embraced to assess the clinical and immunological profile of youth beginning DM in east India.

Methods: Fifty-one successive patients of 7–36-year-old enough with diabetes mellitus going to the Darbhanga Medical College Hospital, Laheriasarai were remembered for the review. All subjects were tried for glutamic acid decarboxylase (GAD), an islet cell antigen ICA512/IA2, and insulin antibodies. Stray and ICA512/IA2 were finished by ELISA and insulin autoantibodies were tried by radioimmunoassay (RIA) technique. These patients were likewise evaluated for hepatitis A to E, cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) as trigger elements for the beginning of type 1 DM.

Results: Of the total 51 patients, 38 were male and 13 were female. The mean age and BMI of the subjects were 19.7 (±7) years and 21 (± 5) kg/m2, separately. Twenty patients were beneath the age of 18 years and their stature was more than 75th percentile of Indian norms. All patients were indicative and 12 of these gave ketoacidosis. Just 48% (n=24) were positive for GAD, 14% (n=7) for ICA512/IA-2, and 28% (n=14) were positive for insulin neutralizer. Five of these patients had proof of hepatitis E virus infection. None of the subjects had proof of dynamic CMV or EBV infection.

Conclusions: About half of the young beginning diabetes mellitus patients from east India had the presence of pancreatic autoimmunity as GAD, ICA512/IA2, and insulin antibodies or a mixture of antibodies reminiscent of having type 1 DM. Further examinations should be done on an enormous example size in various pieces of the country.

Keywords: Anti-GAD antibody, HbA_1C, pancreatic autoantibodies, type 1 diabetes mellitus, youth onset diabetes

INTRODUCTION

The prevalence of diabetes mellitus (DM) is expanding all through the world, particularly in developing nations, including India because of changing ways of life of individuals and hereditary foundations. Diabetes is lopsidedly higher in the youthful grown-up populace in Asian nations dissimilar to in the West, where it is more normal in more seasoned individuals. In 2012, 371 million individuals in the age group 20-79 years were experiencing diabetes with China having the greatest number followed by India1. It will cause

extraordinary monetary weight on well-being assets overall particularly in creating countries [2]. Diabetes in India remembering for a more youthful populace (<25 years) is a disturbing circumstance given its monetary and social effect on society [2, 3]. Studies from India and the USA have shown an expanded predominance of diabetes in the more youthful population [4, 5].



In India, 10% of determined patients to have diabetes were under 30-year-old enough in 2002[6]. The sorts of diabetes in the young populace from India was ordered into old-style type 1, traditional sort 2, ketosis safe youth diabetes, pancreatic diabetes or development beginning diabetes mellitus7. The determination and arrangement of diabetes depend on the clinical and immunological profile of the patients. Immunological markers, like the pancreatic islet cell antibodies, including insulin antibodies, anti-GAD, (glutamic corrosive decarboxylase), and against ICA512/IA2, an islet cell antigen is utilized for separation between various sorts of diabetes in the more youthful population.

Prior investigations have announced clinical profiles and variable rates of counteracting agent inspiration in youth beginning diabetes mellitus from South Asia[8-14]. Nonetheless, none of these examinations has revealed every one of the three antibodies together in youth beginning diabetes mellitus in India. Hereditary foundation inclines an individual toward type 1 DM[15]. Nonetheless, a trigger element is needed for the beginning of diabetes. The most widely recognized trigger element is a viral infection [16]. There is a lack of information on the trigger component for the beginning of type 1 diabetes from India. In this manner, the current review was intended to assess the clinical and immunological profile of patients with youth beginning diabetes mellitus patients from north India.

MATERIAL & METHODS

The review subjects were essential for the Protégé Encore study, aphase3, randomized,

double-blind, multinational, fake treatment-controlled review to assess the viability and security of Teplizumab (MGA031), a humanized, anti- CD3 monoclonal immunizer, in kids and grown-ups with ongoing beginning sort 1 diabetes mellitus [17]. The review populace in this sub review was chosen from Darbhanga Medical College Hospital, Darbhanga, India. The enlistment period was from January to July 2020 and test size depended on the number of patients screened at these two places. Members were qualified assuming they met the accompanying measures: matured 7-36 years; the weight of somewhere around 36 kg; type 1 diabetes mellitus analyzed for 12 weeks or less, with the need for infused insulin treatment; perceivable fasting or animated C-peptide; and positive autoantibody titre against an islet-cell antigen (ICA-512/IA-2), glutamic corrosive decarboxylase (GAD 65), or insulin, inside 2 weeks of starting insulin treatment. Rejection models zeroed in on clinical issues that would possibly jumble results or obstruct safe fruition of the preliminary, including genuine cardiovascular issues, dynamic contaminations, and ongoing investment in a clinical preliminary, inoculation, or pregnancy. Models for a finding of diabetes were according to standard American Diabetes Association (ADA) guidelines [18].

All studies on patients were subjected to clinical and biochemical tests according to the pre-planned case record structure. The lab tests included total blood count, blood glucose levels, kidney and liver capacity tests, lipid profile, HbA1c, and urine for miniature HbA1C egg whites. The immunological profile included the discovery of antibodies against glutamic corrosive decarboxylase (GAD Ab), a tyrosine phosphatase-like protein (ICA 512/IA-2 Ab) and insulin by ELISA method and insulin antibodies were finished by radioimmunoassay (RIA) strategy from units provided by Kronus (Boise, USA). The degrees of three autoantibodies were estimated in an authorized focal research center (Quintiles Laboratories, Singapore). The remove esteems for GAD Ab, ICA512/IA-2 and insulin antibodies were 5 IU/ml, 15 and 0.4 U/ml, separately. Each of the three packs was tried for execution capability before concentrating on the example examination. Adjustment check, awareness, accuracy, and weakening confirmation were assessed. The immunological profile against GAD, anti-ICA512/IA-2 and anti-insulin antibodies were done in all patients. The patients having antibodies alone or mixed were considered as experiencing type 1 DM and the excess patients were named type 2 DM.

Further, all patients were tried for dynamic viral contaminations, for example, hepatitis A-E, cytomegalovirus (CMV), and Epstein-Barr Virus (EBV) by antigen recognition techniques. Hepatitis A counteracting agent complete (anti- HAV aggregate) and hepatitis An IgM neutralizer (against HAV, IgM) were tried by Bayer Chemiluminescence. Subjective immunoassay was utilized for the hepatitis screen board (HBsAg, against HCV). Hepatitis B surface antigen (HBsAg) affirmation was tried by Bayer Chemiluminescence. HCV RIBA was finished by National University Hospital (Singapore). Diasorin EIA (catalyst immunoassay) was utilized for hepatitis D (Delta) immunizer (against D) identification and hepatitis E IgG antibodies were finished by Metropolis (Mumbai, India). Epstein-Barr infection and CMV were tried utilizing polymerase chain response (PCR). IgM and IgG antibodies for EBV and IgG antibodies for CMV were tried in all patients by EIA and immunofluorescence, separately. The institutional morals board supported the review convention, and all members or gatekeepers gave composed informed assent.

STATISTICAL ANALYSIS

Data were analyzed using SSPS for windows 10. Statistical methods used were descriptive to calculate mean ± SD.

RESULTS

Table 1. Baseline characteristics of the study population

Parameters	Total (N 51)	Type 1 DM (N 24)	Type 2 DM (N 27)
Age (yr)	19.72 ± 7.14	17.76 ± 6.52	22.52 ± 7.20*
Height (cm)	162.98 ± 13.01	160.8 ± 13.7	166.2 ± 11.6
Weight (kg)	55.38 ± 16.61	51.67 ± 15.01	60.70 ± 17.70
BMI (kg/m^2)	21.02 ± 4.57	19.70 ± 3.37	21.63 ± 4.61
TSH	11.03 ± 36.49	3.14 ± 3.27	2.30 ± 1.60
Free T4	13.82 ± 3.02	13.72 ± 3.25	13.97 ± 2.74
HBA_1c (%)	11.55 ± 3.15	11.71 ± 3.30	11.34 ± 2.99
Hb (g%)	15.23 ± 8.4	13.45 ± 1.79	17.00 ± 12.68
Urea (mg/dl)	3.98 ± 1.09	4.12 ± 1.09	3.81 ± 1.11
Creatinine (mg/dl)	58.88 ± 15.17	55.90 ± 13.44	63.14 ± 16.78

Hb, haemoglobin; TSH, thyroid stimulating hormone; BMI, body mass index
*P<0.05 compared to type 1DM

Of the absolute 51 subjects, 38 were male and 13 were female. The mean age was 19.72±7.14 years, and BMI was 21.02±4.57 kg/m2. Twenty subjects were beneath the age of 18 and their tallness was more than 75th percentile of Indian principles. Eleven subjects who were under 18-year-old enough had a stature of >75 % percentile according to Indian development graphs. There was no huge contrast in various boundaries in type 1 and type 2 subjects except for the age was fundamentally (P<0.05) higher in the type 2 group. All subjects were suggestive of diabetes and 12 of these patients gave ketoacidosis at the hour of finding. The leftover patients gave osmotic side effects. There was no indication of neuropathy, retinopathy, and nephropathy in these patients at the hour of consideration. The mean HbA1c level of all patients was 11.55 percent. All patients had typical blood counts, lipid profiles, and kidney and liver capacity tests. The mean thyroid stimulating hormone (TSH) level was 11.03±36.49 uIU/ml. Just 12% of patients had hypothyroidism.

Anti-GAD Ab was available in 24 (48%) patients. ICA512/IA2 neutralizer was distinguished in seven (14%) patients, and 14 (28%) patients had insulin antibodies. Seven (14%) patients showed the presence of both enemies of GAD and anti- ICA512/IA2 antibodies and five (9%) patients had both enemies of GAD and insulin antibodies. The presence of each of the three pancreatic antibodies was seen in just three patients.

Neutralizer positive patients were more youthful, had a lower weight and BMI, and most of them gave diabetic ketoacidosis. There was proof of dynamic hepatitis E (IgM immunizer positive) disease in five patients. None of the patients showed proof of dynamic CMV, EBV contamination or other hepatitis disease.

DISCUSSION

The separation somewhere in the range of T1DM and T2DM is troublesome in youthful patients yet should be possible by immunological markers, as an enemy of GAD, ICA512/IA2, and insulin antibodies[19]. In our review, against GAD antibodies were available in 48% of patients, ICA512/IA2 immune response in 14% and insulin immunizer in 28% instances of youth beginning diabetes. Further, dynamic viral contamination, particularly HEV as a potential trigger element for the beginning of T1DM was seen in just 10% of cases.

Autoimmunity in youth beginning has been accounted for before from India and elsewhere[11-13]. The degree of autoimmunity announced in the current review was among the most noteworthy details up to this point contrasted with other Indian studies[7-9]. Kouchipillai et al6 have shown 38% enemy of GAD inspiration in their review. Nonetheless, Pan *et al*[20] revealed predominance as low as 9% in South Indian patients[13]. A review from north India has shown higher qualities, for example, 70% of GAD inspiration and 20-26 percent energy of ICA

neutralizer in type1diabetic patients[20]. Goswami *et al*[7] have announced 24.2 percent pancreatic neutralizer in youth beginning diabetes patients from north India. Different investigations, for example, by Tica *et al*[21] and Thai *et al*[22] have revealed 27 and 39.6 percent inspiration against GAD, individually. Lan *et al*[23] detailed 54.6 percent inspiration against GAD and 24 percent for both enemy of GAD and ICA512/IA2 antibodies. The presence of every one of the three antibodies was seen in just three patients. None of the investigations has dissected all antibodies together for a finding of type1diabetes. In our review, against GAD neutralizer was available in all counteracting agent positive youth beginning DM.

Subsequently, testing for anti-GAD Ab alone may maybe do the trick as an analytic instrument in youth beginning DM. None of the patients showed proof of late EBV and CMV infection diseases. There are no less than two unique pathogenic systems in infection actuated diabetes: cytolytic contamination of beta cells prompting their annihilation, and setting off of autoimmunity prompting the immune system to intervene obliteration of beta cells[24]. No less than 10 infections have been embroiled as setting off factors at the beginning of T1DM. Retrovirus, mumps infection, rubella infection, CMV, enterovirus and EBV are answerable for immune system interceded obliteration of beta cells. Other viral contaminations, for example, encephalomyocarditis infection, Coxsackie B infections can prompt direct harm to beta cell[25-29]. In our review, just five patients had proof of HEV disease proposing its conceivable job in the beginning of immune system DM in youth. Hepatitis C infection contamination has been displayed to play a part in the advancement of T1DM[30-31]. Be that as it may, one more review didn't track down any connection between are any of the viral hepatitis diseases and the beginning of DM[32].

In this study, the heights of T1DM patients was more than 75% percentile of the Indian norm. The increment in stature might be credited to immune system peculiarity working in development speed increase just as creation in antibodies in T1DM[33].

Our review had specific limits. We have not done HLA-composing in this review. Further, there was a choice predisposition as we rejected subjects with indications of insulin obstruction.

CONCLUSION

Taking everything into account, the presence of pancreatic antibodies was seen among half of the adolescent beginning diabetic patients from north India, anti-GAD Ab being the most widely recognized. Comparable investigations ought to be done in different pieces of the country with a huge example size.

REFERENCES

1. IDF Diabetes Atlas, update 2012. International Diabetes Federation. Available from: *http://www.idf.org/ diabetesatlas/5e/Update2012.*
2. Ramachandran A, Das AK, Joshi SR, Yajnik CS, Shah S, Prasanna Kumar KM. Current status of diabetes in India and need for novel therapeutic agents. *J Assoc Physicians India* 2010; *58* : 7-9.
3. Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, *et al.* ICMR-INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research–INdia DIABetes (ICMR-INDIAB) study. *Diabetologia* 2011; *54* : 3022-7.
4. Pettitt DJ, Talton J, Dabelea D, Divers J, Imperatore G, Lawrence JM, *et al*. SEARCH for Diabetes in Youth Study Group. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. *Diabetes Care* 2014; *37* : 402-8.
5. Kochupillai N, Goswami R. Youth-onset diabetes in India: nature of diabetes and use of

bovine insulin in their treatment. *RssDI textbook of diabetes*, April 2002. Available from: *www.iddtindia.org/youth.asp*.

6. Goswami R, Kochupillai N, Gupta N, Kukreja A, Lan M, Maclaren NK. Islet cell autoimmunity in youth onset diabetes mellitus in Northern India. *Diabetes Res Clin Pract* 2001;*53* : 47-54.
7. Baruah MP, Ammini AC, Khurana ML. Demographic, breast- feeding, and nutritional trends among children with type 1 diabetes mellitus. *Indian J Endocrinol Metab* 2011; *15* : 38-42.
8. Jyotsna VP, Singh SK, Gopal D, Unnikrishnan AG, Agrawal NK, Singh SK, *et al*. Clinical and biochemical profiles of young diabetics in North-Eastern India. *J Assoc Physicians India* 2002; *50* : 1130-4.
9. Katulanda P, Shine B, Katulanda GW, Silva A, Asfir EL, Sheriff R, *et al*. Diabetes mellitus among young adults in Sri Lanka-role of GAD antibodies in classification and treatment: The Sri Lanka Young Diabetes study. *Diabetologia* 2008;*51* : 1368-74.
10. Amutha A, Datta M, Unnikrishnan IR, Anjana RM, Rema M, Venkat Narayan KM, *et al*. Clinical profile of diabetes in the young seen between 1992 and 2009 at a specialist diabetes centre in south India. *Prim Care Diabetes* 2011; *5* : 223-9.
11. Thai AC, Mohan V, Khalid BA, Cockram CS, Pan CY, Zimmet P, *et al*. The ASDIAB Study Group. Islet autoimmunity status in Asians with young-onset diabetes (12-40 years): association with clinical characteristics, beta cell function and cardio- metabolic risk factors. *Diabetes Res Clin Pract* 2008; *80* : 224-30.
12. Unnikrishnan AG, Bhatia E, Bhatia V, Bhadada SK, Sahay RK, Kannan A, *et al*. Type 1 diabetes versus type 2 diabetes with onset in persons younger than 20 years of age. *Ann N Y Acad sci* 2008; *1150* : 239-44.
13. Mohan V, Deepa R, Bhatia E, Singh AK, Hitman GA, Zimmet PZ, *et al*. Antibodies to pancreatic islet cell antigens in diabetes seen in Southern India with particular reference to fibrocalculous pancreatic diabetes. *Diabet Med* 1998; *15* : 156-9.
14. Mehra NK, Kumar N, Kaur G, Kanga U, Tandon N. Biomarkers of susceptibility to type 1 diabetes with special reference to the Indian population. *Indian J Med Res* 2007; *125* : 321-44.
15. Galleri L, Sebastiani G, Vendrame F, Grieco FA, Spagnuolo I, Dotta F. Viral infections and diabetes. *Adv Exp Med Biol* 2012; *771* : 252-71.
16. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, *et al*. Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. *Lancet* 2011;*378* : 487-97.
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; *20* : 1183-97.
18. Pan CY, So WY, Khalid BA, Mohan V, Thai AC, Zimmet P, *et al*. Metabolic, immunological and clinical characteristics in newly diagnosed Asian diabetes patients aged 12-40 years. *Diabet Med* 2004; *21* : 1007-13.
19. Mehra NK, Kumar N, Kaur G, Kanga U, Tandon N. Biomarkers of susceptibility to type 1 diabetes with special reference to the Indian population. *Indian J Med Res* 2007; *125* : 321-44.
20. Tica V, Hanif MW, Andersson A, Valsamakis G, Barnett AH, Kumar S, *et al* . Frequency of latent autoimmune diabetes in adults in Asian patients diagnosed as type 2diabetes inet al. Metabolic, immunological and clinical characteristics in newly diagnosed Asi Birmingham, United Kingdom. *Ann N YAcad sci* 2003; *1005* : 356-8.
21. Thai AC, Ng WY, Loke KY, Lee WR, Lui KF, Cheah JS. Anti-GAD antibodies in Chinese patients with youth and adult-onset IDDM and NIDDM. *Diabetologia* 1997; *40*

:1425-30.

22. Lan MS, Wasserfall C, Maclaren NK, Notkins AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. *Proc Natl Acad sci UsA* 1996; *93* : 6367-70.
23. Yoon JW, Ihm SH, Kim KW. Viruses as a triggering factor oftype 1 diabetes and genetic markers related to the susceptibility to the virus-associated diabetes. *Diabetes Res Clin Pract* 1989;*7* (Suppl 1) : S47-58.
24. Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. *Diabetes Metab Res Rev* 2003; *19* : 8-31.
25. Salminen K, Sadeharju K, Lönnrot M, Vähäsalo P, Kupila A, Korhonen S, *et al*. Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birthcohort study. *J Med Virol* 2003; *69 :* 91-8.
26. Lönnrot M, Korpela K, Knip M, Ilonen J, Simell O, Korhonen S, *et al*. Enterovirus infection as a risk factor for β-cell autoimmunity in a prospectively observed birth cohort: The Finnish Diabetes Prediction and Prevention Study. *Diabetes* 2000; *49* : 1314-8.
27. Roivainen M, Rasilainen S, Ylipaasto P, Nissinen R, Ustinov J, Bouwens L, *et al*. Mechanisms of coxsackievirus-induced damage to human pancreatic beta-cells. *J Clin Endocrinol Metab* 2000; *85* : 432-40.
28. Blomqvist M, Juhela S, Erkkilä S, Korhonen S, Simell T, Kupila A, *et al*. Rotavirus infections and development ofdiabetes-associated autoantibodies during the first 2 years of life. *Clin Exp Immunol* 2002; *128* : 511-5.
29. Chen LK, Chou YC, Tsai ST, Hwang SJ, Lee SD. Hepatitis C virus infection-related Type 1 diabetes mellitus. *Diabet Med* 2005; *22* : 340-3.
30. Uto H, Matsuoka H, Murata M, Okamoto T, Miyata Y, Hori T, *et al*. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy. *Diabetes Res Clin Pract* 2000; *49* : 101-6.
31. Atabek ME, Kart H, Erkul I. Prevalence of hepatitis A, B, C and E virus in adolescents with type-1 diabetes mellitus. *Int JAdolesc Med Health* 2003; *15* : 133-7.
32. Songer TJ, LaPorte RE, Tajima N, Orchard TJ, Rabin BS, Eberhardt MS, *et al*. Height at diagnosis of insulin dependent diabetes in patients and their non-diabetic family members. *BrMed J (Clin Res Ed)* 1986; *292* : 1419-22.